Hynda K. Kleinman received an MS and a Ph.D from Massachusetts Institute of Technology in 1971 and 1974, respectively. After a postdoctoral fellowship at Tufts University from 1973-1975, she directed a research lab at the NIH from 1975-2006. She has published over 430 papers and has 9 patents, 2 of which have been successfully commercialized. Matrigel is used worldwide for various in vitro/in vivo assays and was among the top 15 NIH patents bearing royalties for many years. The regenerative protein thymosin beta 4 is currently in phase 3 trials for ocular injuries. She has received numerous national/international awards for her scientific accomplishments, including the Hildegard Doerenkamp-Gerhardt Zbinden Award for developing “an in vitro assay for screening anti-cancer compounds which spares animals”. She received the Debio Peptide Award for identifying a peptide which inhibits cancer growth and metastases, the WISE (Women in Science and Engineering) Award for “being the most outstanding woman scientist in the federal government”, and the Senior Woman in Science Award from the American Society for Cell Biology for “her scientific achievement and strong commitment to the fostering of women in science.” She is currently a consultant to various biotech companies, including Bioqual Inc, Polaryx® Therapeutics, RegeneRx Biopharmaceuticals, Inc., and etc.